FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

708 letters match. Newest first.

  1. Everlaan Organics, Inc. dba Maple Organics

    FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.

    High risk
  2. ABBE Laboratories, Inc.

    FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.

    High risk
  3. Spectra Therapy, LLC

    FDA warns Spectra Therapy over LASERwrap infrared lamp device quality-system violations and unapproved disease-treatment claims.

    High risk
  4. Gussyup LLC dba Private Label Grooming

    FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.

    High risk
  5. Oasis Medical, Inc.

    FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.

    High risk
  6. Shiva Analyticals Private Limited

    FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.

    High risk
  7. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  8. Glenmark Pharmaceuticals Limited

    FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.

    High risk
  9. Medical Chemical Corporation

    FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.

    High risk
  10. Nature’s Fusions LLC

    FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.

    High risk
  11. Daewoo Pharmaceutical Co., Ltd.

    FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.

    High risk
  12. Libby Laboratories, Inc.

    FDA warned Libby Laboratories of Berkeley, California, that its drug manufacturing violated CGMP, including releasing a hospital antiseptic without microbial testing.

    High risk
  13. Xtreme Tools International, Inc.

    FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.

    High risk
  14. Dynamic Blending Specialists, Inc.

    FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.

    High risk
  15. Voehlganic Farm LLC

    FDA warned Voehlganic Farm LLC that its shell eggs are adulterated because it lacked a Salmonella Enteritidis prevention plan and testing.

    High risk
  16. Exela Pharma Sciences, LLC

    Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.

    High risk
  17. InVia Fertility Specialists, PLLC

    FDA warned InVia Fertility Specialists over reproductive tissue donor eligibility and missing infectious disease testing.

    High risk
  18. Healwell Homeo Private Limited

    FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.

    High risk
  19. Pushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi

    FDA warns Turkish OTC drug wipe maker Pushclean over missing finished-product and component testing.

    High risk
  20. Aju Pharm Co., Ltd.

    FDA warns Aju Pharm over unvalidated Fixone suture anchors and multiple quality-system failures.

    High risk
  21. Horizon Tool Inc.

    FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.

    High risk
  22. Laboratoire Druide Inc.

    FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.

    High risk
  23. Amish Origins Management, LLC

    FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.

    High risk
  24. American Behavioral Research Institute, LLC

    FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.

    High risk
  25. CTK OTC Laboratories LLC formerly FMK LABS, Inc.

    CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.

    High risk
  26. Evi Labs LLC

    FDA warns Evi Labs over OTC drug manufacturing failures, including an antiperspirant lot above the aluminum chlorohydrate limit.

    High risk
  27. Zhejiang Easyclean Daily Chemical Co., Ltd

    FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.

    High risk
  28. Huangshi Hygienic Material Medicine Co., Ltd.

    Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.

    High risk
  29. Golden Grains Bakery

    FDA warns Golden Grains Bakery over repeated preventive-control failures for RTE Blender Bombs, including metal detection and Listeria risks.

    High risk
  30. NeuroSync, Inc.

    FDA warned NeuroSync, Inc. that its EYE-SYNC eye-assessment device was adulterated by design control, CAPA, supplier and acceptance failures, plus unreported correction and missing UDI.

    High risk
  31. Product Society LLC

    FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.

    High risk
  32. Wuxi Medical Instrument Factory Co., Ltd.

    FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.

    High risk
  33. NWL Netherlands Services B.V.

    FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.

    High risk
  34. Skye Biologics Holdings LLC

    FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.

    High risk
  35. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk
  36. Mentha & Allied Products Private Ltd.

    FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.

    High risk
  37. Shantou S.E.Z. Baojie Industry Co., Ltd.

    FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.

    High risk
  38. Taizhou Jingshang Cosmetics Technology Co., Ltd.

    FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

    High risk
  39. BioAsia Worldwide Sdn Bhd

    FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.

    High risk
  40. Cosco International, Inc.

    FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.

    High risk
  41. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  42. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  43. PMS4PMS, LLC

    FDA warns PMS4PMS of Clarence, NY, over CGMP failures and an unapproved menstrual cramp relief cream.

    High risk
  44. Nubratori, Inc. dba Nubratori Rx

    FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.

    High risk
  45. Yangzhou Sion Commodity Co., Ltd.

    FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.

    High risk
  46. Dexcom, Inc.

    FDA warned Dexcom over quality-system and design-control failures for G6 and G7 glucose monitors, including an unapproved sensor component change.

    High risk
  47. Hangzhou Glamcos Biotech Co., Ltd.

    Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.

    High risk
  48. Advanced Pharmaceutical Technology

    FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.

    High risk
  49. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk
  50. International Laboratories Corp

    FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.

    High risk